Agile Therapeutics, Inc. announced a new alliance with Afaxys Pharma, LLC to promote Twirla® (levonorgestrel and ethinyl estradiol) transdermal system. Every year, more than 31 million Americans rely on community and public health centers to get essential care. This agreement expands access of Twirla in the U.S. family planning community and for the patients who rely on healthcare in this setting.

As a trusted expert in community and public health, Afaxys is a leading provider of innovative contraceptive options, which will now include Twirla, an effective, low-dose contraceptive option in a non-daily, non-invasive patch.